

Joel C Gelfand

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8846931/publications.pdf>

Version: 2024-02-01

282
papers

26,050
citations

5891

81
h-index

7340

152
g-index

305
all docs

305
docs citations

305
times ranked

15339
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Myocardial Infarction in Patients With Psoriasis. JAMA - Journal of the American Medical Association, 2006, 296, 1735.	3.8	1,571
2	Prevalence of cardiovascular risk factors in patients with psoriasis. Journal of the American Academy of Dermatology, 2006, 55, 829-835.	0.6	889
3	Psoriasis and comorbid diseases. Journal of the American Academy of Dermatology, 2017, 76, 377-390.	0.6	706
4	Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. European Heart Journal, 2010, 31, 1000-1006.	1.0	577
5	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Journal of the American Academy of Dermatology, 2019, 80, 1029-1072.	0.6	542
6	The Risk of Depression, Anxiety, and Suicidality in Patients With Psoriasis. Archives of Dermatology, 2010, 146, 891-5.	1.7	530
7	Prevalence and Treatment of Psoriasis in the United Kingdom. Archives of Dermatology, 2005, 141, 1537-41.	1.7	512
8	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2009, 61, 451-485.	0.6	505
9	Epidemiology of psoriatic arthritis in the population of the United States. Journal of the American Academy of Dermatology, 2005, 53, 573.e1-573.e13.	0.6	499
10	The Risk of Mortality in Patients With Psoriasis. Archives of Dermatology, 2007, 143, 1493-9.	1.7	489
11	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2009, 60, 643-659.	0.6	419
12	The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004. Journal of the American Academy of Dermatology, 2009, 60, 218-224.	0.6	417
13	Psoriasis Severity and the Prevalence of Major Medical Comorbidity. JAMA Dermatology, 2013, 149, 1173.	2.0	402
14	Guidelines of care for the management of psoriasis and psoriatic arthritis. Journal of the American Academy of Dermatology, 2011, 65, 137-174.	0.6	398
15	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. Journal of the American Academy of Dermatology, 2008, 58, 1031-1042.	0.6	383
16	Patient burden and quality of life in atopic dermatitis in US adults. Annals of Allergy, Asthma and Immunology, 2018, 121, 340-347.	0.5	383
17	Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom. Journal of Investigative Dermatology, 2012, 132, 556-562.	0.3	377
18	Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 326-332.	0.5	373

#	ARTICLE	IF	CITATIONS
19	Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K.. <i>British Journal of Dermatology</i> , 2010, 163, 586-592.	1.4	369
20	The Risk of Stroke in Patients with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2009, 129, 2411-2418.	0.3	358
21	Adalimumab for the Treatment of Moderate to Severe Hidradenitis Suppurativa. <i>Annals of Internal Medicine</i> , 2012, 157, 846.	2.0	349
22	Guidelines of care for the management of psoriasis and psoriatic arthritis. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 114-135.	0.6	311
23	Determinants of quality of life in patients with psoriasis: A study from the US population. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 704-708.	0.6	305
24	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1073-1113.	0.6	281
25	Evaluation of AJCC Tumor Staging for Cutaneous Squamous Cell Carcinoma and a Proposed Alternative Tumor Staging System. <i>JAMA Dermatology</i> , 2013, 149, 402.	2.0	277
26	Attributable Risk Estimate of Severe Psoriasis on Major Cardiovascular Events. <i>American Journal of Medicine</i> , 2011, 124, 775.e1-775.e6.	0.6	267
27	The Risk of Lymphoma in Patients with Psoriasis. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2194-2201.	0.3	265
28	Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. <i>Journal of Investigative Dermatology</i> , 2019, 139, 583-590.	0.3	254
29	The prevalence of psoriasis in African Americans: Results from a population-based study. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 23-26.	0.6	250
30	Increased Risk for Demyelinating Diseases in Patients With Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2005, 129, 819-826.	0.6	241
31	Obesity and the risk of psoriatic arthritis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1273-1277.	0.5	239
32	Prevalence of the Metabolic Syndrome in Psoriasis. <i>Archives of Dermatology</i> , 2011, 147, 419.	1.7	236
33	Determinants of Compliance with Anticoagulation: A Case-Control Study. <i>American Journal of Medicine</i> , 1997, 103, 11-17.	0.6	230
34	Lymphoma Rates Are Low but Increased in Patients With Psoriasis. <i>Archives of Dermatology</i> , 2003, 139, 1425-9.	1.7	226
35	Psoriasis and metabolic disease: epidemiology and pathophysiology. <i>Current Opinion in Rheumatology</i> , 2008, 20, 416-422.	2.0	223
36	The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2011, 64, 1035-1050.	0.6	197

#	ARTICLE	IF	CITATIONS
37	Systemic and Vascular Inflammation in Patients With Moderate to Severe Psoriasis as Measured by [18F]-Fluorodeoxyglucose Positron Emission Tomography â€“Computed Tomography (FDG-PET/CT). Archives of Dermatology, 2011, 147, 1031.	1.7	194
38	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology, 2020, 82, 1445-1486.	0.6	184
39	Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovascular Research, 2019, 115, 721-728.	1.8	178
40	Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma. Blood, 2015, 126, 1452-1461.	0.6	174
41	Impact of atopic dermatitis on health-related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey. Journal of the American Academy of Dermatology, 2017, 77, 274-279.e3.	0.6	166
42	Severity of Psoriasis Associates With Aortic Vascular Inflammation Detected by FDG PET/CT and Neutrophil Activation in a Prospective Observational Study. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2667-2676.	1.1	155
43	Psoriasis and comorbid diseases. Journal of the American Academy of Dermatology, 2017, 76, 393-403.	0.6	152
44	AJC Editor's Consensus: Psoriasis and Coronary Artery Disease. American Journal of Cardiology, 2008, 102, 1631-1643.	0.7	148
45	Consensus Guidelines for the Management of Plaque Psoriasis. Archives of Dermatology, 2012, 148, 95.	1.7	148
46	Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ, The, 2013, 347, f5961-f5961.	3.0	145
47	Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. Journal of the American Academy of Dermatology, 2008, 58, 625-631.	0.6	141
48	The Risk of Cancer in Patients With Psoriasis. JAMA Dermatology, 2016, 152, 282.	2.0	140
49	From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. Journal of the American Academy of Dermatology, 2017, 76, 290-298.	0.6	137
50	Joint AADâ€“NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. Journal of the American Academy of Dermatology, 2021, 84, 432-470.	0.6	135
51	National Psoriasis Foundation Clinical Consensus on Disease Severity. Archives of Dermatology, 2007, 143, 239-42.	1.7	132
52	Association of Biologic Therapy With Coronary Inflammation in Patients With Psoriasis as Assessed by Perivascular Fat Attenuation Index. JAMA Cardiology, 2019, 4, 885.	3.0	132
53	Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis, 2012, 224, 218-221.	0.4	131
54	Symptoms and diagnosis of anxiety and depression in atopic dermatitis in U.S. adults. British Journal of Dermatology, 2019, 181, 554-565.	1.4	131

#	ARTICLE	IF	CITATIONS
55	Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. <i>Rheumatology</i> , 2014, 53, 346-352.	0.9	129
56	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 161-201.	0.6	129
57	Prevalence and treatment patterns of psoriatic arthritis in the UK. <i>Rheumatology</i> , 2013, 52, 568-575.	0.9	118
58	Surrogate End Points for the Treatment of Diabetic Neuropathic Foot Ulcers. <i>Diabetes Care</i> , 2003, 26, 1696-1700.	4.3	116
59	Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study. <i>European Heart Journal</i> , 2018, 39, 3608-3614.	1.0	115
60	Effect of 2 Psoriasis Treatments on Vascular Inflammation and Novel Inflammatory Cardiovascular Biomarkers. <i>Circulation: Cardiovascular Imaging</i> , 2018, 11, e007394.	1.3	115
61	Increased Risk of Diabetes Mellitus and Likelihood of Receiving Diabetes Mellitus Treatment in Patients With Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 995-1000.	1.7	113
62	Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 604-612.e3.	0.5	111
63	Ultraviolet germicidal irradiation: Possible method for respirator disinfection to facilitate reuse during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1511-1512.	0.6	110
64	From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 94-105.	0.6	109
65	Surrogate Endpoints for the Treatment of Venous Leg Ulcers. <i>Journal of Investigative Dermatology</i> , 2002, 119, 1420-1425.	0.3	108
66	Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 64-72.	0.6	107
67	Psoriasis in the US Medicare Population: Prevalence, Treatment, and Factors Associated with Biologic Use. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2955-2963.	0.3	107
68	Joint American Academy of Dermatologyâ€“National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 775-804.	0.6	105
69	Biologic therapy adherence, discontinuation, switching, and restarting among patients with psoriasis in the US Medicare population. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 1057-1065.e4.	0.6	102
70	Research gaps in psoriasis: Opportunities for future studies. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 146-167.	0.6	101
71	A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 565-573.	0.6	98
72	Incidence and Management of Cardiovascular Risk Factors in Psoriatic Arthritis and Rheumatoid Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2017, 69, 51-57.	1.5	98

#	ARTICLE	IF	CITATIONS
73	Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 149-153.	0.5	96
74	GlycA Is a Novel Biomarker of Inflammation and Subclinical Cardiovascular Disease in Psoriasis. <i>Circulation Research</i> , 2016, 119, 1242-1253.	2.0	95
75	Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 842-849.	0.9	94
76	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2315-2321.	0.3	94
77	Validity of The Health Improvement Network (THIN) for the study of psoriasis. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	91
78	Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. <i>British Journal of Dermatology</i> , 2011, 165, 465-473.	1.4	91
79	Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis. <i>JAMA Cardiology</i> , 2017, 2, 1013.	3.0	90
80	Immunosuppressant Medications and Mortality in Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 1428-1435.	0.2	88
81	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1254-1268.	0.6	88
82	The epidemiology of psoriasis. <i>Expert Review of Dermatology</i> , 2006, 1, 63-75.	0.3	87
83	Psoriasis and the risk of diabetes: A prospective population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 315-322.e1.	0.6	86
84	Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 623-632.	0.6	85
85	Pediatric Psoriasis Comorbidity Screening Guidelines. <i>JAMA Dermatology</i> , 2017, 153, 698.	2.0	84
86	A Phase IV, Randomized, Double-Blind, Placebo-Controlled Crossover Study of the Effects of Ustekinumab on Vascular Inflammation in Psoriasis (the VIP-U Trial). <i>Journal of Investigative Dermatology</i> , 2020, 140, 85-93.e2.	0.3	83
87	Pain Is a Common and Burdensome Symptom of Atopic Dermatitis in United States Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2699-2706.e7.	2.0	82
88	Comparative Effectiveness of Commonly Used Systemic Treatments or Phototherapy for Moderate to Severe Plaque Psoriasis in the Clinical Practice Setting. <i>Archives of Dermatology</i> , 2012, 148, 487.	1.7	81
89	The relationship between duration of psoriasis, vascular inflammation, and cardiovascular events. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 650-656.e3.	0.6	81
90	Cross-Cultural Inequivalence of Dermatology-Specific Health-Related Quality of Life Instruments in Psoriasis Patients. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2315-2322.	0.3	80

#	ARTICLE	IF	CITATIONS
91	Methicillin-Resistant <i>Staphylococcus aureus</i> Colonization in Children with Atopic Dermatitis. <i>Pediatric Dermatology</i> , 2008, 25, 528-534.	0.5	80
92	Effect of Psoriasis Severity on Hypertension Control. <i>JAMA Dermatology</i> , 2015, 151, 161.	2.0	80
93	Physical trauma recorded in primary care is associated with the onset of psoriatic arthritis among patients with psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 521-525.	0.5	77
94	The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 54-61.e1.	0.6	77
95	Risk of Incident Liver Disease in Patients with Psoriasis, Psoriatic Arthritis, and Rheumatoid Arthritis: A Population-Based Study. <i>Journal of Investigative Dermatology</i> , 2018, 138, 760-767.	0.3	75
96	Metabolic Syndrome in Patients with Psoriatic Disease. <i>Journal of rheumatology Supplement, The</i> , 2012, 89, 24-28.	2.2	74
97	Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practice. <i>British Journal of Dermatology</i> , 2014, 170, 672-680.	1.4	74
98	Effectiveness of Online vs In-Person Care for Adults With Psoriasis. <i>JAMA Network Open</i> , 2018, 1, e183062.	2.8	73
99	Burden of illness in adults with atopic dermatitis: Analysis of National Health and Wellness Survey data from France, Germany, Italy, Spain, and the United Kingdom. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 187-195.	0.6	71
100	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. <i>JAMA Dermatology</i> , 2019, 155, 448.	2.0	69
101	Incidence and Prevalence of Juvenile Idiopathic Arthritis Among Children in a Managed Care Population, 1996-2009. <i>Journal of Rheumatology</i> , 2013, 40, 1218-1225.	1.0	68
102	Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts. <i>Journal of the American Academy of Dermatology</i> , 2005, 52, 715-716.	0.6	67
103	Development and Validation of an Algorithm to Accurately Identify Atopic Eczema Patients in Primary Care Electronic Health Records from the UK. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1655-1662.	0.3	67
104	Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 119-123.	0.5	67
105	Product of the Physician Global Assessment and body surface area: A simple static measure of psoriasis severity in a longitudinal cohort. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 931-937.	0.6	64
106	OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 115-122.	0.6	62
107	The risk of fracture among patients with psoriatic arthritis and psoriasis: a population-based study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 882-885.	0.5	62
108	The epidemiology of atopic dermatitis. <i>Clinics in Dermatology</i> , 2003, 21, 109-115.	0.8	61

#	ARTICLE	IF	CITATIONS
109	Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 633-641.	0.6	61
110	A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S). <i>Journal of Investigative Dermatology</i> , 2020, 140, 1784-1793.e2.	0.3	61
111	Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis. <i>Rheumatology</i> , 2017, 56, 907-911.	0.9	59
112	Unraveling Vascular Inflammation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1403-1412.	1.2	59
113	Risk of Serious Infection, Opportunistic Infection, and Herpes Zoster among Patients with Psoriasis in the United Kingdom. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1726-1735.	0.3	57
114	Patient-Reported Outcomes and Health-Care Resource Utilization in Patients with Psoriasis Treated with Etanercept: Continuous versus Interrupted Treatment. <i>Value in Health</i> , 2008, 11, 400-407.	0.1	56
115	Endothelial Cell, Platelet, and Monocyte/Macrophage-Derived Microparticles are Elevated in Psoriasis Beyond Cardiometabolic Risk Factors. <i>Journal of the American Heart Association</i> , 2014, 3, e000507.	1.6	56
116	Neutrophil Subsets, Platelets, and Vascular Disease in Psoriasis. <i>JACC Basic To Translational Science</i> , 2019, 4, 1-14.	1.9	56
117	Is there truly a risk of lymphoma from biologic therapies?. <i>Dermatologic Therapy</i> , 2009, 22, 418-430.	0.8	55
118	Distribution of atopic dermatitis lesions in United States adults. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1341-1348.	1.3	54
119	Psoriasis and Cardiovascular Risk: Strength in Numbers. <i>Journal of Investigative Dermatology</i> , 2010, 130, 919-922.	0.3	53
120	Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis. <i>Circulation Research</i> , 2018, 123, 1244-1254.	2.0	53
121	Association Between Aortic Vascular Inflammation and Coronary Artery Plaque Characteristics in Psoriasis. <i>JAMA Cardiology</i> , 2018, 3, 949.	3.0	53
122	Complementary and alternative medicine for psoriasis: A qualitative review of the clinical trial literature. <i>Journal of the American Academy of Dermatology</i> , 2009, 61, 841-856.	0.6	51
123	Familial Basaloid Follicular Hamartoma. <i>American Journal of Dermatopathology</i> , 2003, 25, 130-137.	0.3	50
124	Test Characteristics of High-Resolution Ultrasound in the Preoperative Assessment of Margins of Basal Cell and Squamous Cell Carcinoma in Patients Undergoing Mohs Micrographic Surgery. <i>Dermatologic Surgery</i> , 2009, 35, 9-16.	0.4	48
125	Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. <i>Pharmacoepidemiology and Drug Safety</i> , 2014, 23, 918-922.	0.9	48
126	Psoriasis and Cardiovascular Risk: Strength in Numbers, Part II. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1007-1010.	0.3	47

#	ARTICLE	IF	CITATIONS
127	The impact of psoriasis on 10-year Framingham risk. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, 796-798.	0.6	47
128	Use of complementary and alternative medicine among adults with skin disease: Results from a national survey. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 419-425.	0.6	46
129	Quantification of Atherosclerotic Plaque Activity and Vascular Inflammation using [18-F] Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT). <i>Journal of Visualized Experiments</i> , 2012, , e3777.	0.2	46
130	The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 677-679.	0.6	46
131	Health Utility Scores of Atopic Dermatitis in US Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1246-1252.e1.	2.0	45
132	Assessing Long-Term Drug Safety: Lessons (Re) Learned from Raptiva. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2010, 29, 16-19.	1.6	43
133	Chronic skin inflammation accelerates macrophage cholesterol crystal formation and atherosclerosis. <i>JCI Insight</i> , 2018, 3, .	2.3	43
134	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1704-1716.	0.6	43
135	HIV-positive patients in Botswana state that mobile teledermatology is an acceptable method for receiving dermatology care. <i>Journal of Telemedicine and Telecare</i> , 2011, 17, 338-340.	1.4	42
136	Content and construct validity, predictors, and distribution of self-reported atopic dermatitis severity in US adults. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 729-734.e4.	0.5	42
137	Atopic Dermatitis in US Adults: From Population to Health Care Utilization. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1524-1532.e2.	2.0	42
138	The epidemiology of sunburn in the US population in 2003. <i>Journal of the American Academy of Dermatology</i> , 2006, 55, 577-583.	0.6	40
139	Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, 376-386.	0.6	40
140	Reliability and Convergent Validity of the Cutaneous Sarcoidosis Activity and Morphology Instrument for Assessing Cutaneous Sarcoidosis. <i>JAMA Dermatology</i> , 2013, 149, 550.	2.0	40
141	Objective Measures of Psoriasis Severity Predict Mortality: A Prospective Population-Based Cohort Study. <i>Journal of Investigative Dermatology</i> , 2018, 138, 228-230.	0.3	40
142	Severity strata for POEM, PO-SCORAD, and DLQI in US adults with atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 464-468.e3.	0.5	40
143	High Clinical Response Rate of Sarcoid Syndrome to Immunomodulatory Therapies. <i>Archives of Dermatology</i> , 2011, 147, 1410.	1.7	38
144	Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1672-1679.e1.	0.3	38

#	ARTICLE	IF	CITATIONS
145	Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 863-865.	0.6	37
146	Psoriasis and Cardiovascular Risk: Strength in Numbers Part 3. <i>Journal of Investigative Dermatology</i> , 2015, 135, 2148-2150.	0.3	36
147	Clinical factors associated with subclinical spread of in situ melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 707-713.	0.6	36
148	High Prevalence of Aquagenic Wrinkling of the Palms in Patients with Cystic Fibrosis and Association with Measurable Increases in Transepidermal Water Loss. <i>Pediatric Dermatology</i> , 2012, 29, 560-566.	0.5	35
149	The Psychometric Properties of the Psoriasis Disability Index in United States Patients. <i>Journal of Investigative Dermatology</i> , 2005, 125, 665-672.	0.3	34
150	Prospective Cohort Study Investigating Changes in Body Image, Quality of Life, and Self-Esteem Following Minimally Invasive Cosmetic Procedures. <i>Dermatologic Surgery</i> , 2018, 44, 1121-1128.	0.4	34
151	Patterns and predictors of atopic dermatitis disease control past childhood: An observational cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 778-780.e6.	1.5	34
152	Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1636-1643.	0.6	34
153	Update on the Natural History and Systemic Treatment of Psoriasis. <i>Advances in Dermatology</i> , 2008, 24, 171-196.	2.0	33
154	Reliability, validity and responsiveness to change of the Patient Report of Extent of Psoriasis Involvement (PREPI) for measuring body surface area affected by psoriasis. <i>British Journal of Dermatology</i> , 2010, 162, 835-842.	1.4	33
155	OBSERVE-5 interim analysis: An observational postmarketing safety registry of etanercept for the treatment of psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 756-764.	0.6	31
156	Stigmatizing attitudes toward persons with psoriasis among laypersons and medical students. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1556-1563.	0.6	31
157	Recommendations for phototherapy during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 287-288.	0.6	31
158	Clinical and pathologic factors associated with subclinical spread of invasive melanoma. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 714-721.	0.6	30
159	Seeing red: flushing out instigators of niacin-associated skin toxicity. <i>Journal of Clinical Investigation</i> , 2010, 120, 2651-2655.	3.9	30
160	Does biologic therapy impact the development of PsA among patients with psoriasis?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 80-86.	0.5	29
161	Synthetic Imidazoquinolines Potently and Broadly Activate the Cellular Immune Response of Patients with Cutaneous T-Cell Lymphoma: Synergy with Interferon- γ Enhances Production of Interleukin-12. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 524-534.	1.4	28
162	Diagnostic Prevalence of Ankylosing Spondylitis Using Computerized Health Care Data, 1996 to 2009: Underrecognition in a US Health Care Setting. , 2016, 20, 15-151.		28

#	ARTICLE	IF	CITATIONS
163	Variations in risk of asthma and seasonal allergies between early- and late-onset pediatric atopic dermatitis: A cohort study. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 634-640.	0.6	28
164	Association of change in clinical status and change in the percentage of the CD4+CD26 ^{hi} lymphocyte population in patients with SÅ©zary syndrome. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 428-434.	0.6	27
165	Srcsm Corrects Fyn-induced Epidermal Hyperplasia by Kinase Down-regulation. <i>Journal of Biological Chemistry</i> , 2007, 282, 1161-1169.	1.6	27
166	Reliability and Validity of Mobile Tele dermatology in Human Immunodeficiency Virusâ€“Positive Patients in Botswana. <i>JAMA Dermatology</i> , 2014, 150, 601.	2.0	27
167	Impact of Biological Agents on Imaging and Biomarkers of Cardiovascular Disease in Patients with Psoriasis: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2402-2411.	0.3	27
168	Stimulated rat mast cells generate histamine-releasing peptide from albumin. <i>Peptides</i> , 1993, 14, 117-123.	1.2	26
169	Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 1167-1175.	0.6	26
170	Psoriasis, Type 2 Diabetes Mellitus, and Obesity. <i>JAMA Dermatology</i> , 2016, 152, 753.	2.0	26
171	Self-reported depression in psoriasis is associated with subclinical vascular diseases. <i>Atherosclerosis</i> , 2016, 251, 219-225.	0.4	26
172	Visceral Adiposity in Psoriasis is Associated With Vascular Inflammation by 18F-Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Beyond Cardiometabolic Disease Risk Factors in an Observational Cohort Study. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 349-357.	2.3	26
173	A randomized, double-blind comparison of the total dose of 1.0% lidocaine with 1:100,000 epinephrine versus 0.5% lidocaine with 1:200,000 epinephrine required for effective local anesthesia during Mohs micrographic surgery for skin cancers. <i>Journal of the American Academy of Dermatology</i> , 2009, 60, 444-452.	0.6	25
174	Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2013, 68, 262-269.	0.6	25
175	Correlation Between Appropriate Use Criteria and the Frequency of Subclinical Spread or Reconstruction With a Flap or Graft for Melanomas Treated With Mohs Surgery With Melanoma Antigen Recognized by T Cells 1 Immunostaining. <i>Dermatologic Surgery</i> , 2016, 42, 471-476.	0.4	25
176	Machine Learning Applications in the Evaluation and Management of Psoriasis: A Systematic Review. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 147-159.	0.3	25
177	Spectrum of virucidal activity from ultraviolet to infrared radiation. <i>Photochemical and Photobiological Sciences</i> , 2020, 19, 1262-1270.	1.6	25
178	Identification of Risk Factors for Psoriatic Arthritis. <i>Archives of Dermatology</i> , 2010, 146, 785-8.	1.7	24
179	Mental health impairment among children with atopic dermatitis: A United States population-based cross-sectional study of the 2013-2017 National Health Interview Survey. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1368-1375.	0.6	24
180	Metabolic syndrome and its factors are associated with noncalcified coronary burden in psoriasis: An observational cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1329-1338.	0.6	24

#	ARTICLE	IF	CITATIONS
181	Effect of UV-B Phototherapy on Plasma HIV Type 1 RNA Viral Level: A Self-controlled Prospective Study. Archives of Dermatology, 1998, 134, 940-5.	1.7	21
182	Synergistic enhancement of cellular immune responses by the novel Toll receptor 7/8 agonist 3M-007 and interferon- β : implications for therapy of cutaneous T-cell lymphoma. Leukemia and Lymphoma, 2011, 52, 1970-1979.	0.6	21
183	Measurement Properties of the Hospital Anxiety and Depression Scale Used in Atopic Dermatitis in Adults. Journal of Investigative Dermatology, 2019, 139, 1388-1391.	0.3	21
184	The risk of respiratory tract infections in patients with psoriasis treated with interleukin 23 pathway-inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making during the COVID-19 pandemic. Journal of the American Academy of Dermatology, 2020, 83, 1523-1526.	0.6	21
185	Patient-Reported Outcome Measures as Complementary Information to Clinician-Reported Outcome Measures in Patients With Psoriasis. JAMA Dermatology, 2021, 157, 1236.	2.0	21
186	The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study. British Journal of Dermatology, 2017, 176, 1366-1369.	1.4	20
187	Body surface area affected by psoriasis and the risk for psoriatic arthritis: a prospective population-based cohort study. Rheumatology, 2022, 61, 1877-1884.	0.9	20
188	Curcuminoids activate p38 MAP kinases and promote UVB-dependent signalling in keratinocytes. Experimental Dermatology, 2010, 19, 493-500.	1.4	19
189	Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis: A Set of Parallel Case-control Studies. Journal of Rheumatology, 2022, 49, 53-59.	1.0	19
190	Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time. JCI Insight, 2020, 5, .	2.3	19
191	Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study*. British Journal of Dermatology, 2022, 186, 664-672.	1.4	19
192	Effect of Wax Epilation Before Hair Removal With a Long-Pulsed Alexandrite Laser: A Pilot Study. Dermatologic Surgery, 2003, 29, 118-123.	0.4	17
193	Diet and Weight Loss as a Treatment for Psoriasis. Archives of Dermatology, 2010, 146, 544-6.	1.7	17
194	Commentary: Does biologic treatment of psoriasis lower the risk of cardiovascular events and mortality?. Journal of the American Academy of Dermatology, 2018, 79, 69-70.	0.6	17
195	Influence of "Not Relevant" Responses on the Dermatology Life Quality Index (DLQI) for Patients With Psoriasis in the United States. JAMA Dermatology, 2019, 155, 743.	2.0	17
196	Association Between Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 and Coronary Artery Disease in Psoriasis. JAMA Dermatology, 2020, 156, 151.	2.0	17
197	Use of primary care services among patients with chronic skin disease seen by dermatologists. JAAD International, 2021, 2, 31-36.	1.1	17
198	Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis: Findings from an observational cohort study. Journal of Cardiovascular Computed Tomography, 2021, 15, 372-379.	0.7	17

#	ARTICLE	IF	CITATIONS
199	Evaluation of a Case Series of Patients With Generalized Pustular Psoriasis in the United States. <i>JAMA Dermatology</i> , 2022, 158, 73.	2.0	17
200	Evaluation of the Dermatology Life Quality Index scoring modification, the DLQI score, in two independent populations. <i>British Journal of Dermatology</i> , 2019, 180, 939-940.	1.4	16
201	Health care utilization for psoriasis in the United States differs by race: An analysis of the 2001-2013 Medical Expenditure Panel Surveys. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 200-203.	0.6	15
202	Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. <i>JAMA Dermatology</i> , 2022, 158, 252.	2.0	15
203	Atopic dermatitis disease control and age: A cohort study. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 190-192.e3.	1.5	14
204	Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1674-1680.	1.3	14
205	The UK General Practice Research Database. , 0, , 337-346.		14
206	Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis: A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 161-163.	0.6	13
207	Generation of a Tropoelastin mRNA Variant by Alternative Polyadenylation Site Selection in Sun-Damaged Human Skin and Ultraviolet B-Irradiated Fibroblasts. <i>Biochemical and Biophysical Research Communications</i> , 1998, 246, 217-221.	1.0	12
208	High-Density Lipoprotein Cholesterol Function Improves after Successful Treatment of Psoriasis: A Step Forward in the Right Direction. <i>Journal of Investigative Dermatology</i> , 2014, 134, 592-595.	0.3	12
209	Psoriasis: a novel risk factor for type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 919-921.	5.5	12
210	Validation and Interpretation of Short Form 12 and Comparison with Dermatology Life Quality Index in Atopic Dermatitis in Adults. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2090-2097.e3.	0.3	12
211	Association between atopic dermatitis and learning disability in children. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2808-2810.	2.0	12
212	Psoriasis and Psoriatic Arthritis. <i>American Journal of Preventive Medicine</i> , 2013, 44, 424-426.	1.6	11
213	Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 923-930.	0.6	11
214	Influenza Vaccination Rates in Adults with Psoriasis Compared to Adults with Other Chronic Diseases. <i>Journal of Investigative Dermatology</i> , 2019, 139, 473-475.	0.3	11
215	Evaluation of the Frequency of "Not Relevant" Responses on the Dermatology Life Quality Index by Sociodemographic Characteristics of Patients With Psoriasis. <i>JAMA Dermatology</i> , 2020, 156, 446.	2.0	11
216	Evaluation of a Case Series of Patients With Palmoplantar Pustulosis in the United States. <i>JAMA Dermatology</i> , 2022, 158, 68.	2.0	11

#	ARTICLE	IF	CITATIONS
217	Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015, 73, 868-870.	0.6	10
218	Responsiveness of the EuroQol 5â€Dimension 3â€Level instrument, Dermatology Life Quality Index () Tj ETQq0 0 0 rgBT /Overlock 10 Tf <i>Journal of Dermatology</i> , 2019, 181, 1088-1090.	1.4	10
219	Responsiveness to Change and Establishment of the Minimal Clinically Important Difference for the Cutaneous Sarcoidosis Activity and Morphology Instrument. <i>JAMA Dermatology</i> , 2020, 156, 98.	2.0	10
220	Long-term Treatment for Severe Psoriasis. <i>Archives of Dermatology</i> , 2007, 143, 1191-3.	1.7	9
221	Population Variations in Rheumatoid Arthritis Treatment and Outcomes, Northern California, 1998â€2009. , 2016, 20, 4-12.		9
222	Cells of Myeloid Origin Partly Mediate the Association between Psoriasis Severity and CoronaryâPlaque. <i>Journal of Investigative Dermatology</i> , 2020, 140, 912-915.e1.	0.3	9
223	Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 591-598.	0.8	9
224	High frequency ultrasound: a novel instrument to quantify granuloma burden in cutaneous sarcoidosis. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , 2017, 34, 136-141.	0.2	9
225	VIGNETTES. <i>Archives of Dermatology</i> , 2005, 141, 1321.	1.7	8
226	Retrospective Analysis of Beta-Blocker Instituted for Treatment of Hemangiomas (RABBIT Study). <i>Clinical Pediatrics</i> , 2014, 53, 1084-1090.	0.4	8
227	Assessing Cutaneous Psoriasis Activity Using FDG-PET. <i>Clinical Nuclear Medicine</i> , 2015, 40, 727-729.	0.7	8
228	Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII. <i>American Journal of Hematology</i> , 2016, 91, 1107-1112.	2.0	7
229	National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2017, 2, 73-80.	0.3	7
230	Research Techniques Made Simple: Pharmacoepidemiology Research Methods inâDermatology. <i>Journal of Investigative Dermatology</i> , 2018, 138, e13-e18.	0.3	7
231	Headâ€toâ€head trials of systemic psoriasis therapies: a systematic review of study design and maximum acceptable treatment differences. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 42-55.	1.3	7
232	Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 709-716.	0.6	7
233	Relationship between chronic stress-related neural activity, physiological dysregulation and coronary artery disease in psoriasis: Findings from a longitudinal observational cohort study. <i>Atherosclerosis</i> , 2020, 310, 37-44.	0.4	7
234	Opioid prescribing in adults with and without psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1777-1779.	0.6	7

#	ARTICLE	IF	CITATIONS
235	Dermatologist response rates to a mailed questionnaire: A randomized trial of monetary incentives. <i>Journal of the American Academy of Dermatology</i> , 2012, 66, e18-e20.	0.6	6
236	Clinical Research after COVID-19: Embracing a New Normal. <i>Journal of Investigative Dermatology</i> , 2021, 141, 481-483.	0.3	6
237	Srcasm overexpression in psoriasis-insights into pathogenesis. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 160-165.	0.7	5
238	Dermatologist Preferences for Treatments to Compare in Future Randomized Controlled Comparative Effectiveness Trials for Moderate to Severe Psoriasis. <i>Archives of Dermatology</i> , 2012, 148, 539.	1.7	5
239	Using Hawthorne Effects to Improve Adherence in Clinical Practice: Lessons From Clinical Trials Reply. <i>JAMA Dermatology</i> , 2013, 149, 490.	2.0	5
240	Outcomes Research in Psoriasis and Psoriatic Arthritis Using Large Databases and Research Networks: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1233-1236.	1.0	5
241	Dermatofibrosarcoma protuberans (DFSP) with fibrosarcomatous changes in a patient with psoriasis treated with adalimumab. <i>JAAD Case Reports</i> , 2015, 1, 272-273.	0.4	5
242	Aortic valve stenosis: a new cardiovascular comorbidity of psoriasis?. <i>European Heart Journal</i> , 2015, 36, 2134-2135.	1.0	5
243	Measuring niacin-associated skin toxicity (NASTy) stigmata along with symptoms to aid development of niacin mimetics. <i>Journal of Lipid Research</i> , 2017, 58, 783-797.	2.0	5
244	How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 569-572.	0.6	5
245	Prevalence of clinically significant incidental findings by whole-body fludeoxyglucose F 18 positron emission tomography/computed tomography scanning in moderate-to-severe psoriasis patients participating in clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1630-1639.	0.6	5
246	Subclinical Liver Disease Is Associated with Subclinical Atherosclerosis in Psoriasis: Results from Two Observational Studies. <i>Journal of Investigative Dermatology</i> , 2022, 142, 88-96.	0.3	5
247	Association of S100A8/A9 with Lipid-Rich Necrotic Core and Treatment with Biologic Therapy in Patients with Psoriasis: Results from an Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2909-2919.	0.3	5
248	Treatment of Bullous Pemphigoid With Topical Corticosteroids: Review of a Randomized Controlled Trial. <i>Archives of Dermatology</i> , 2002, 138, 1236-7.	1.7	4
249	Reliability and Validity of a Photographic Method for Measuring Facial Hair Density in Men. <i>Archives of Dermatology</i> , 2011, 147, 1328.	1.7	4
250	Validity of diagnostic codes for identifying cutaneous squamous cell carcinoma in The Health Improvement Network. <i>British Journal of Dermatology</i> , 2017, 176, 1363-1365.	1.4	4
251	Building a Citizen Pscientist: Advancing Patient-Centered Psoriasis Research by Empowering Patients as Contributors and Analysts. <i>Dermatology and Therapy</i> , 2018, 8, 405-423.	1.4	4
252	Engaging the Patient's Perspective in Clinical Trials Research. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1217-1220.	0.3	4

#	ARTICLE	IF	CITATIONS
253	Anticipated and Perceived Stigma Among Patients With Psoriasis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 93-99.	0.3	4
254	Psoriasis and its impact on the clinical outcome of patients with pulmonary embolism. <i>International Journal of Cardiology</i> , 2021, 343, 114-121.	0.8	4
255	Exploring Priority Research Areas in Psoriasis and Psoriatic Arthritis from Dermatologistsâ€™ Perspective: A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2204-2210.	1.0	3
256	A Randomized, Double-blind, Placebo-Controlled Proof of Concept Trial of Topical Cidofovir, 1% and 3%, for the Prevention of Beard Hair Growth in Men. <i>Archives of Dermatology</i> , 2012, 148, 257.	1.7	3
257	Counterpoint: A tale of two meta-analyses revisited. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 381-383.	0.6	3
258	Treat-to-target and Improving Outcomes in Psoriasis: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1037-1040.	1.0	3
259	Prevalence of Dermatitis Herpetiformis Within the iCureCeliac Patient-Powered Research Networkâ€™ Patient Characteristics and Dietary Counseling. <i>JAMA Dermatology</i> , 2020, 156, 1374.	2.0	3
260	Treatment utilization and drug survival of systemic medications among commercially insured children with psoriasis. <i>Pediatric Dermatology</i> , 2021, 38, 1169-1177.	0.5	3
261	Eruption of human immunodeficiency virus seroconversion. <i>International Journal of Dermatology</i> , 1998, 37, 436-438.	0.5	3
262	Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons Living With Psoriatic Disease. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2022, 7, 174-186.	0.3	3
263	Impaired Coronary Blood Flow in Patients with Psoriasis: Findings from an Observational Cohort Study. <i>Journal of Investigative Dermatology</i> , 2021, 141, 913-916.	0.3	2
264	Response to â€œKidney disease in moderate-to-severe psoriasis: a critical appraisalâ€™. <i>British Journal of Dermatology</i> , 2016, 174, 270-271.	1.4	1
265	Commentary. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e161-e162.	0.6	1
266	Counselling patients for return to work on immunosuppression: practices of Canadian specialists during the COVID-19 pandemic. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 874-878.	0.4	1
267	Is It Prime Time for Statin Therapy in Psoriasis?. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1519-1522.	0.3	1
268	The pitfalls of a purely clinical definition of nephrogenic systemic fibrosis: Comment on the article by Todd et al. <i>Arthritis and Rheumatism</i> , 2008, 58, 1552-1552.	6.7	0
269	Adherence to Treatment: Still the Forgotten Variableâ€™ Reply. <i>Archives of Dermatology</i> , 2010, 146, .	1.7	0
270	Avoiding palmar ambiguity in the PREPI: a handprint is approximately 1% body surface area - Reply. <i>British Journal of Dermatology</i> , 2011, 164, no-no.	1.4	0

#	ARTICLE	IF	CITATIONS
271	Addressing Comorbid Diseases in Patients with Moderate-to-Severe Psoriasis. Psoriasis Forum, 2013, 19a, 182-186.	0.1	0
272	OPO311...Physical Trauma is Associated with the Onset of Psoriatic Arthritis Among Psoriasis Patients. Annals of the Rheumatic Diseases, 2015, 74, 190.3-191.	0.5	0
273	Reply to: "Statistical and methodological issues". Journal of the American Academy of Dermatology, 2017, 77, e115-e116.	0.6	0
274	Outcomes of Comorbidities with Biologic and Systemic Agents. , 2018, , 65-71.		0
275	Reply to: "Do IL-17 inhibitors increase risk of respiratory tract infections?". Journal of the American Academy of Dermatology, 2020, 83, e305-e306.	0.6	0
276	In response to: "Reply to research letter". Journal of the American Academy of Dermatology, 2020, 83, e445.	0.6	0
277	Association Between Early Severe Cardiovascular Events and Ustekinumab Treatment?. JAMA Dermatology, 2021, 157, 123.	2.0	0
278	Response to: "Successful implementation of phototherapy guidelines during the COVID-19 pandemic". Journal of the American Academy of Dermatology, 2021, 85, e321.	0.6	0
279	Response to: "Methotrexate Use and Liver Outcomes in Psoriasis and Rheumatoid Arthritis Patients: A Commentary on "Risk of liver disease in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis receiving methotrexate: A population-based study". Journal of the American Academy of Dermatology, 2021, 85, e401.	0.6	0
280	Top-Accessed Article: Psoriasis Associated With Hyperleptinemia. Archives of Dermatology, 2010, 146, .	1.7	0
281	New insights into psoriasis comorbidity. , 0, , .		0
282	New insights into psoriasis comorbidity. , 0, , .		0